Breakthrough study reveals genetic keys to psoriasis severity and treatment

A major study led by Newcastle University and Queen Mary University of London has uncovered key genetic clues that could transform psoriasis treatment. The research reveals how metabolic and immune factors influence disease severity, offering hope for more targeted therapies. Psoriasis, which affects around two percent of the UK population, remains a lifelong condition with no permanent cure.

The team analysed gene expression patterns in both affected and unaffected skin, as well as blood samples, using advanced computational methods and artificial intelligence. Their findings highlighted a 14-gene signature linked to body mass index (BMI) in healthy-looking skin, which also correlated with worse disease severity in inflamed areas. This suggests metabolic dysregulation plays a role in how psoriasis progresses.

Two specific genetic variants, HLADQA101 and HLADRB115, were strongly tied to more severe baseline symptoms. Additionally, the study pinpointed a 9-gene biomarker panel that could help classify patients based on disease activity levels. Such molecular markers may pave the way for personalised treatment strategies, reducing side effects and improving outcomes.

Blood tests further uncovered an immune-related gene pattern that only appeared after patients received the biologic drug adalimumab. This indicates certain white blood cell populations are activated or altered by the treatment. The study's extensive data repository is now available to researchers worldwide, enabling deeper exploration of psoriasis-related gene pathways.

The findings provide a scientific foundation for developing stratified medicine approaches in psoriasis care. By identifying genetic and molecular markers, clinicians may soon tailor treatments more precisely to individual patients. The research also underscores the condition's complexity, linking metabolic health, immune responses, and genetic factors to disease severity.